Literature DB >> 12672065

The IL-1 receptor 1 is critical for Th2 cell type airway immune responses in a mild but not in a more severe asthma model.

Nicole Schmitz1, Michael Kurrer, Manfred Kopf.   

Abstract

IL-1 alpha and IL-1 beta are potent pro-inflammatory cytokines that regulate many physiological systems by binding and signaling to the same receptor termed IL-1 receptor type 1 (IL-1R1). We have investigated the role of IL-1 for pulmonary immune responses in models of allergic asthma using IL-1R1-deficient (IL-1R1(-/-)) mice. In a model of mild asthma, based on repeated sensitization of mice with low doses of ovalbumin in the absence of any adjuvant and multiple intranasal challenges, the pulmonary eosinophilic inflammation and goblet cell hyperplasia were strongly reduced in IL-1R1(-/-) as compared to control BALB/c mice. Moreover, priming of CD4(+) T cells in bronchial lymph nodes and their recruitment to the lung was affected in IL-1R1(-/-) mice associated with impaired antibody responses including IgG, IgE, and IgA. In contrast, sensitization of mice in the presence of alum adjuvant, a more severe asthma model, rendered the IL-1 pathway dispensable for the development of pulmonary allergic Th2 responses, as eosinophilic inflammation, antibody responses, and CD4(+) T cell priming in lymph nodes were comparable between IL-1R1(-/-) and wild-type mice. These results suggest a critical role of IL-1/IL-1R1 for development of allergic Th2 responses, but its requirement can be overcome by using alum as adjuvant for sensitization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672065     DOI: 10.1002/eji.200323801

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  42 in total

Review 1.  Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.

Authors:  Kristina Ludigs; Valeriy Parfenov; Renaud A Du Pasquier; Greta Guarda
Journal:  Cell Mol Life Sci       Date:  2012-04-24       Impact factor: 9.261

Review 2.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

3.  Inflammasome Activity in Non-Microbial Lung Inflammation.

Authors:  Jennifer L Ather; Rebecca A Martin; Karina Ckless; Matthew E Poynter
Journal:  J Environ Immunol Toxicol       Date:  2014-09-20

Review 4.  Old and new adjuvants.

Authors:  Amy S McKee; Philippa Marrack
Journal:  Curr Opin Immunol       Date:  2017-07-19       Impact factor: 7.486

Review 5.  The IL-1 family: regulators of immunity.

Authors:  John E Sims; Dirk E Smith
Journal:  Nat Rev Immunol       Date:  2010-01-18       Impact factor: 53.106

6.  Alveolar macrophages from allergic lungs are not committed to a pro-allergic response and can reduce airway hyperresponsiveness following ex vivo culture.

Authors:  P Pouliot; A Spahr; E Careau; V Turmel; E Y Bissonnette
Journal:  Clin Exp Allergy       Date:  2008-01-14       Impact factor: 5.018

7.  The inflammasome and alum-mediated adjuvanticity.

Authors:  Suk-Jo Kang; Richard M Locksley
Journal:  F1000 Biol Rep       Date:  2009-02-24

Review 8.  Type I IL-1 receptor (IL-1RI) as potential new therapeutic target for bronchial asthma.

Authors:  Jyh-Hong Lee; Li-Chieh Wang; Hsin-Hui Yu; Yu-Tsan Lin; Yao-Hsu Yang; Bor-Luen Chiang
Journal:  Mediators Inflamm       Date:  2010-07-05       Impact factor: 4.711

9.  Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells.

Authors:  Amy S McKee; Matthew A Burchill; Michael W Munks; Lei Jin; John W Kappler; Rachel S Friedman; Jordan Jacobelli; Philippa Marrack
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-27       Impact factor: 11.205

10.  IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation.

Authors:  Shlomo Z Ben-Sasson; Jane Hu-Li; Juan Quiel; Stephane Cauchetaux; Maya Ratner; Ilana Shapira; Charles A Dinarello; William E Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.